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ABSTRACT 
Objective: The aims this study was to determine the effect of lipid ratio Monostearin and Miglyol 808 roomates gives the 
physical stability after storage 40 days. Methods: The NLC making was done by using emulsification method in the 
formation of NLC meloxicam, 3 different lipid ratios were used, including ratios of 6: 4, 7: 3, 8: 2. Results: NLC meloxicam 
physical stability of the pH, viscosity, particle size, particle morphology and entrapment efficiency. NLC meloxicam 
belongs to semisolid preparations with pH value range of 5.72-5.87. Increasing viscosity of NLC system is caused by the 
increase of solid lipid. The measurement results of particle size of three different lipid formulas indicated that the lipid 
particle size was <1000 nm. Entrapment efficiency test of all NLC-lipid compositions revealed quite high result (> 
80%). Conclusion: The system uses lipid monostearin NLC meloxicam and Miglyol 808 at a ratio of 8: 2 is the most 
optimal combination shows physical stability after storage 40 days. 
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INTRODUCTION 
Meloxicam belongs to a group of Non-Steroidal Anti-
Inflammatory Drugs. Meloxicam can be used in 
rheumathoid arthritis therapy. However, the use of oral 
meloxicam causes gastrointestinal irritation side effects1. 
The topical use of meloxicam can be delivery solutions of 
NSAID drug, directly to the target disease and provide a 
local effect. This method can also avoid the existence of 
gastrointestinal side effects because it is not absorbed 
systemically. Meloxicam has a characteristic which is not 
soluble in water and has a logP value of 3:42, so in a 
preparation mostly consisting of water, the solubility of 
meloxicam would be very small and with the logP values, 
it means that meloxicam is non-polar. Therefore, the 
development of this meloxicam topical delivery systems. 
One of delivery system was selected is Solid Lipid 
Nanoparticle (SLN). 
Solid Lipid Nanoparticle (SLN) is colloidal dispersion in 
nano size consists of a solid lipid stabilized by surfactants 
that work in the interface area3. Some advantages of SLN, 
for instance the ability to protect the active compounds 
from degradation, controlled release, the ability to load a 
lipophilic or hydrophilic material, non-toxic and did not 
irritate3. Limitations of SLN systems included loading 
capacity of the active ingredient was limited and the 
expulsion of active ingredient during storage. This was 
because of the high orderdness of the lattice crystal of solid 
lipid so that the active ingredient which has been entrapped 
easily squeezed out of the system. To overcome the 
limitations of the system SLN, a second-generation 
nanoparticle system that is nanostructured lipid carrier 
(NLC) was developed6. NLC are formed with both liquid 
and solid lipid as a blend mixture in such a ratio that they 
are solid at room temperature. The active ingridient can be 
incorporated in particle matrix in a molecular dispersed 
form or it can be arranged as amorphous cluster6. 
The NLC manufacturing is done by mixing solid lipid in 
an amount greater than the liquid lipid. This research used 
solid lipid (Monostearin), liquid lipid (Miglyol 808) with a 
ratio of 6: 4, 7: 3, and 8; 2, surfactant (Tween 80) and 
meloxicam as the active ingredient. Evaluation conducted 
in this study included physicochemical characteristics after 
strorage 40 days.  
 
MATERIALS AND METHODS 
Materials 
The main materials used in this study is meloxicam (Apex 
Healthcare Limited), Monostearin (Sigma Aldrich), 
Miglyol 808 (Sigma Aldrich), Tween 80 (PT Croda), pro 
analysis Ethanol (Merck), Buffer component: 
KH 2 PO 4 and NaOH pro analysis (Merck). 
Methods 
Preparation NLC System of Meloxicam 
The Manufacturing of NLC meloxicam 
This study used emulsification 
method (emulsification). Meloxicam-NLC system was 
made by melting the lipid phase (Monostearin and Miglyol 
808) with different lipid ratios (6: 4, 7: 3 and 8: 2), and 
meloxicam at temperatures of 65 ° C. At the same time, a 
solution of surfactant (Tween-80 and phosphate buffer pH  
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Table 2: The results of pH measurements of the 
meloxicam NLC system of formula 1, formula 2 and 
formula 3 on days 1, 20, and 40 
Day Formula Average pH ± SD 
1 
  
2 (7: 3) 5.73 ± 0.03 
3 (8: 2) 5.75 ± 0.01 
20 1 (6: 4) 5.74 ± 0.04 
2 (7: 3) 5.74 ± 0.04 
3 (8: 2) 5.85 ± 0.03 
40 1 (6: 4) 5.83 ± 0.02 
2 (7: 3) 5.85 ± 0.02 
3 (8: 2) 5.87 ± 0.02 
   
6.0 ± 0.05), was prepared and heated at a temperature of 
65 ° C Hot surfactant solution then was dispersed into the 
hot lipid phase by using ultra-turax with a speed of 3400 
rpm For 30 minutes. The next stage was cooling stage, then 
it was stirred using a magnetic stirrer at 100 rpm until it 
Reached the temperature of 25 o C. The fixed NLC was 
measured to Determine the end weight of the NLC4,10. 
Evalution of the Physical Stability of NLC Meloxicam 
All NLC-MLX were evalution of physical stability before 
and after storage 40 days in their pH, viscosity, particles 
size, and entrapment efficiency. 
Determination of pH 
Determining pH of each test preparation was done using a 
pH meter. 
Examination of the particle size and size distribution 
Examination of the particle size consisting of two 
treatments before and after UVB irradiated for 21 hours. 
Each sample was diluted to 200 ppm stirring for 3 minutes 
at 500 rpm. Dilution checked by Delsa Nano Particle Size 
on the angle of 65o and a temperature of 25o C. Data  
Table 4 Measurement results of entrapment efficiency 
of meloxicam NLC system on days 1, 20, and 40 
Day Formula Trapping Rate (%) ± SD 
1 
2 (7: 3) 90.831 ± 0.180 
3 (8: 2) 94.358 ± 0.109 
20 
1 (6: 4) 88.848 ± 0.522 
2 (7: 3) 91,561 ± 0.412 
3 (8: 2) 95,703 ± 0,510 
40 
1 (6: 4) 90.996 ± 0.440 
2 (7: 3) 94.343 ± 0.168 
3 (8: 2) 95,850 ± 0.535 
   
obtained were average particle diameter and Polydispersity 
Index (PI). All measurement was replicated 3 times. 
Percentage of Drug Entrapment (Loading capacity) 
Drug entrapment efficiency was determined by 
centrifugation method. It was calculated from the ratio of 
the medicinal amount in NLC to total added drug 
amount. Centrifugation was carried out using Hettich 
Rotofix 32 Centrifuge. About 1 gm of NLC dispersion 
containing the drug was placed in the centrifuge tube, and 
sample were centrifuged at 2,500 rpm for 45 minutes. The 
amount of the free drug in the supernatant was estimated 
at 362 nm by spectrophotometry. 
 
RESULT AND DISCUSSION 
Determination of pH after storage 
The pH-measurement results of each of the formulas after 
storage for 40 days can be seen in Table 2. Based on the 
results of statistical analysis ANOVA two way on pH 
testing NLC meloxicam on day 1, day 20 and day 40 
showed that there was no difference in pH change 
significantly during storage, as shown by F value of 0,579 
Table 1: The formula of NLC meloxicam. 
Ingredient Function Concentrate 
range (%) 
Concentrate (% -w/ w) 
Formulation I Formulation II Formulation III 
Meloxicam Active ingredient 
 
1 1 1 
Monostearin Solid Lipid 6 * 6 7 8 
Miglyol 808 Liquid Lipid 3-4 * 4 3 2 






      
 
Table 3 The results of particle size measurements and polypspersity index of NLC meloxicam system of formula 1, 
formula 2, and formula 3 on days 1, 20, and 40 
Day Formula Particle Size (nm) ± SD Polidispersitas Index ± SD 
1 
1 (6 : 4) 518.9 ± 291.3 0.299 ± 0.236 
2 (7 : 3) 472.1 ± 107.1 0.616 ± 0.092 
3 (8 : 2) 421.9 ± 137.1 421.9 ± 137.1 
20 
1 (6 : 4) 244.2 ± 23.2 0.438 ± 0.054 
2 (7 : 3) 235.4 ± 41.6 0.650 ± 0.251 
3 (8 : 2) 416.3 ± 143.4 0.495 ± 0.155 
40 
1 (6 : 4) 333.9 ± 104.0 0.474 ± 0.097 
2 (7 : 3) 404.0 ± 240.8 0.565 ± 0.171 
3 (8 : 2) 610.0 ± 126.6 0.510 ± 0.207 
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and significant against α = 0.05 (0.571). The p value for 
the formula* day is 0.958, it can be concluded that there is 
no significant pH difference between formula 1, formula 2 
and formula 3 on storage time (days). After 40 days of 
storage it can be concluded that the meloxicam NLC 
system formed shows the stability of the Meloxicam NLC 
system in the absence of pH change. 
Examination of the particle size and size distribution 
The result of measuring the particle size of each formula 
after storage for 40 days can be seen in Table 3. Based on 
the results of two-way ANOVA statistical analysis particle 
size measurements obtained F value of 2.861 and 
significant to α = 0.05 (0.083). The p value for the 
formula* day is 0.390, it can be concluded that there is no 
significant particle size difference between formula 1, 
formula 2, and formula 3 on storage time (days). This 
shows that there is no significant difference in particle size 
of formula 1, formula 2, and formula 3 during storage from 
Day 1, 20th, and 40th. After 40 days of storage it can be 
concluded that the meloxicam NLC system formed shows 
the stability of the system NLC in the absence of particle 
size changes. 
Measurement of Drug Entrapment efficiency After Storage 
40 Days 
The measurement of trapping efficiency of each of the 
formulas after storage for 40 days can be seen in Table 4. 
Based on the results of two-way ANOVA statistical 
analysis trapping efficiency measurements obtained F 
value of 113.06 and significant to α = 0.05 (0.000), 
demonstrating the difference between the trapping 
efficiency of the storage time the 1st, 20th, and to- 40. This 
difference in the efficiency of the trapping is indicated by 
the increase in trap efficiency after 40 days of storage, 
indicating that the meloxicam NLC system formed 
remains stable with no reduction in trap efficiency. 
 
CONCLUSION 
NLC system of meloxicam using lipid Monostearin and 
Miglyol 808 ratio of 8: 2 is the most optimal combination, 
because it shows physicochemical characteristics 
according to the criteria of NLC system of meloxicam  the 
post 40-day-storage. 
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